Last reviewed · How we verify

NCT05347082

Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment

Completed NA Last updated 6 May 2022
What this trial tests

NA trial testing Cholecalciferol in Postmenopausal Osteoporosis in 47 participants. Completed in 20 February 2022.

Timeline
29 April 2021
Primary endpoint
29 December 2021
20 February 2022

Quick facts

Lead sponsorHospital Regional 1o de Octubre
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment47
Start date29 April 2021
Primary completion29 December 2021
Estimated completion20 February 2022
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Regional 1o de Octubre

Who can join

Eligibility, female only, with Postmenopausal Osteoporosis or Postmenopause. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world. Chronic exposure to the parathyroid hormone (PTH) is catabolic for the bone, worsening the state of osteoporosis. However, it is unclear whether these conditions could significantly improve bone mineral density (BMD). In the present work, it was shown that the resolution of hyperparathyroidism in postmenopausal women improves osteoporosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cholecalciferol

Trials testing the same drug.

Other recruiting trials for Postmenopausal Osteoporosis

Currently open trials in the same condition.

Other Hospital Regional 1o de Octubre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing